A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Japan

Toyama University Hospital, Toyama, Toyama